{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:35:13Z","timestamp":1793367313086,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Korea Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HA22C0098"],"award-info":[{"award-number":["HA22C0098"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejso.2026.112030","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:03:45Z","timestamp":1784559825000},"page":"112030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting OPTIMIST trial imaging criteria for pathologic complete response to neoadjuvant therapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Ji-Jung","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme Natasha K.","family":"Paggao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0376-2209","authenticated-orcid":false,"given":"Na Hye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Gon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-2777","authenticated-orcid":false,"given":"Nariya","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-6065","authenticated-orcid":false,"given":"Heera","family":"Yoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0152-575X","authenticated-orcid":false,"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.112030_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2026.112030_bib2","first-page":"229","article-title":"Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery","volume":"4","author":"De Lena","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/j.ejso.2026.112030_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1008337009350","article-title":"Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergoni\u00e9 Bordeaux Groupe Sein (IBBGS)","volume":"10","author":"Mauriac","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-016-0684-6","article-title":"Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials","volume":"18","author":"van la Parra","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejso.2026.112030_bib5","article-title":"Accuracy of tumor bed biopsy for predicting pathologic complete response after chemotherapy among women with breast cancer: complete responders in the breast study","volume":"9","author":"Hariharan","year":"2023","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.09.034","article-title":"Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?","volume":"69","author":"Heil","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2026.112030_bib7","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112030_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-020-05678-3","article-title":"Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial","volume":"182","author":"Lee","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2026.112030_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.suronc.2020.10.002","article-title":"Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy","volume":"35","author":"Narui","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108277","article-title":"Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy","volume":"50","author":"Tasoulis","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1245\/s10434-021-10847-9","article-title":"Vacuum-assisted breast biopsy after neoadjuvant systemic treatment for reliable exclusion of residual cancer in breast cancer patients","volume":"29","author":"Koelbel","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10549-012-2180-8","article-title":"Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction","volume":"136","author":"Lobbes","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2026.112030_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2026.112030_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1186\/s12885-015-1664-4","article-title":"Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis","volume":"15","author":"Marinovich","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.112030_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1634\/theoncologist.2015-0353","article-title":"FDG-PET\/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies","volume":"21","author":"Sheikhbahaei","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejso.2026.112030_bib16","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s00330-017-5251-8","article-title":"Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour","volume":"28","author":"Kim","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ejso.2026.112030_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4048\/jbc.2023.0265","article-title":"Omission of breast surgery in predicted pathologic complete response after neoadjuvant systemic therapy: a multicenter, Single-Arm, non-inferiority trial","volume":"27","author":"Jung","year":"2024","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ejso.2026.112030_bib18","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1245\/s10434-009-0334-7","article-title":"Ki-67 expression gives additional prognostic information on St. Gallen 2007 and adjuvant! online risk categories in early breast cancer","volume":"16","author":"Jung","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.112030_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.4103","article-title":"Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict residual cancer","volume":"155","author":"Tasoulis","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejso.2026.112030_bib21","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1007\/s00330-023-09547-7","article-title":"Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis","volume":"33","author":"Ploumen","year":"2023","journal-title":"Eur Radiol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:46:15Z","timestamp":1793364375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0748798326006499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112030","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting OPTIMIST trial imaging criteria for pathologic complete response to neoadjuvant therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112030"}}